Article citationsMore >>

Chen YC, Chang HY, Deng JS, et al. Hispolon from Phellinus linteus induces G0/G1 cell cycle arrest and apoptosis in NB4 human leukemia cells. Am J Chin Med 2013; 41(6): 1439-57.

has been cited by the following article:

Article

Alternative Therapeutic Approach to Urothelial Cell Carcinoma with Medicinal Mushroom Extracts

1Department of Urology, New York Medical College, Valhalla, New York, USA


Journal of Cancer Research and Treatment. 2016, Vol. 4 No. 5, 73-79
DOI: 10.12691/jcrt-4-5-1
Copyright © 2016 Science and Education Publishing

Cite this paper:
Amul Bhalodi, Mark Ferretti, Matthew Chaimowitz, Muhammad Choudhury, John Phillips, Sensuke Konno. Alternative Therapeutic Approach to Urothelial Cell Carcinoma with Medicinal Mushroom Extracts. Journal of Cancer Research and Treatment. 2016; 4(5):73-79. doi: 10.12691/jcrt-4-5-1.

Correspondence to: Sensuke  Konno, Department of Urology, New York Medical College, Valhalla, New York, USA. Email: sensuke_konno@nymc.edu

Abstract

Severe side effects from chemotherapy or immunotherapy often limit their clinical utility in urothelial cell carcinoma of the bladder. To explore alternative therapies, we were particularly interested in one of medicinal mushrooms called Phellinus linteus (PL) with antitumor/anticancer activity. We investigated possible anticancer effects of three distinct extracts or fractions of PL using an urothelial cell carcinoma (UCC) model in vitro. Those fractions included PL-I (crude extract), PL-II (water-extracted), and PL-III (ethanol-extracted), which were tested for their antiproliferative effects on UCC cells. To explore the anticancer mechanism(s) of these fractions, cell cycle analysis and analyses of epigenetic parameters, caspases-3 and -9, and apoptotic regulators, were also performed. Both PL-I and -II induced a maximum growth reduction of ~60% at 700 µg/ml while PL-III led to a ~90% growth reduction at 150 µg/ml in 72 h. Cell cycle analysis indicated that cells treated with 500 µg/ml (IC50) of PL-I and -II or 60 µg/ml (IC50) of PL-III underwent a G1 cell cycle arrest, accompanied by the up-regulation of p21, a cell cycle-dependent kinase inhibitor. Additionally, histone deacetylase (HDAC) activity was significantly (>60%) lost, while both histones H3 and H4 were highly acetylated, indicating alterations in the chromatin structure. Moreover, both caspases-3 and -9 in cells treated with each IC50 of three PL-fractions were all significantly (p<0.03) activated, implying induction of apoptosis. The present study shows that all three PL-fractions, PL-I, -II, and -III, have anticancer effects on UCC cells, although PL-III appears to be the most potent. Such an anticancer mechanism is attributed to a p21-mediated cell cycle arrest with epigenetic modifications involving HDAC inactivation and hyperacetylation of H3 and H4, ultimately leading to apoptotic cell death. Therefore, PL-fractions may have clinical implications in a safer and improved therapeutic modality for urothelial cell carcinoma.

Keywords